ナトリウム・グルコース共輸送体2阻害薬 SGLT2 inhibitor
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Eng J Med. 2017 Jun 12. doi: 10.1056/NEJMoa1611925. [Epub ahead of print] Neal B et al. www.ncbi.nlm.nih.gov PMID: 28605608 ClinicalTrials.gov No.: NCT01032629(CANVAS…
Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials. Monami M et al. Acta Diabetol. 2017 Jan;54(1):19-36. doi: 10.1007/s00592-016-0892-7. Epub 2016 Aug 4. www.n…
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. Zinman B et al.; EMPA-REG OUTCOME Investigators. N Engl J Med. 2015 Nov 26;373(22):2117-28. www.ncbi.nlm.nih.govPMID: 26378978 ClinicalTrials.gov No.: NCT01131676 【…